Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspecs Group Regulatory News (SPEC)

Share Price Information for Inspecs Group (SPEC)

Share Price is delayed by 15 minutes
Get Live Data
84.50    0.00 (0.00%)
Bid:
82.00
Ask:
87.00
Spread: 5.00 (6.098%)
Market Cap: £85.91m
SPEC Live PriceLast checked at - London Stock Exchange

Intraday Inspecs Group Share Chart

Trading Update

30 Jan 2025 07:00

RNS Number : 1945V
Inspecs Group PLC
30 January 2025
 

30 January 2025

Inspecs Group plc

("INSPECS" or "the Group")

 

Full Year Trading Update

 

Inspecs Group plc, a leading designer, manufacturer and distributor of eyewear (sunglasses, optical frames, lenses and low vision products), today announces a trading update for the year ended 31 December 2024 ahead of reporting its final results on 10 April 2025.

 

Summary

·

Group revenue of £200.5m (2023: £203.3m) and Underlying EBITDA of £17.5m (2023: £18.0m)

·

H2 2024 revenue increase of 5.9% to £97.5m (H2 2023: £92.1m)

·

Gross profit margin increased from 50.9% to 51.4%

·

Reduced net debt (excluding leases) by £1.3m to £22.9m (2023: £24.2m)

·

Integration of US businesses completed in 2024 and now fully amalgamated

·

The new facility in Vietnam is now fully operational, with promising enquiries to utilise the enlarged manufacturing capacity

·

Eschenbach Optics division has performed strongly, particularly in the US and Europe, with our new digital low vision aids well received by the market

·

European business continues to take market share despite an overall soft market

·

Renewed and extended Group banking facilities to 2027 with HSBC

 

Revenue and Underlying EBITDA

Group revenue for the year was £200.5m (2023: £203.3m) and on a constant currency basis1, revenue increased £2.3m to £205.6m. The Group expects to deliver an Underlying EBITDA of £17.5m (2023: £18.0m) in line with recently updated market expectations2. The Group is targeting revenue growth in 2025 together with improving EBITDA margin as key priorities.

 

Financial position

The Group's net debt (excluding leases) decreased by £1.3m during the year to £22.9m (31 December 2023: £24.2m). The Group invested a further £0.7m in the new Vietnam factory as planned to provide additional capacity with improved sustainable efficiency, and a further £1.9m on deferred and contingent acquisition consideration.

 

Financial funding and liquidity

The Group successfully refinanced its existing banking arrangements with HSBC UK Bank plc in December, extending their maturity to 2027.

 

The debt facilities consist of a three-year Multicurrency Revolving Credit Facility and a Term Loan predominantly drawn in Euros and, as a result, the Group expects to reduce its interest costs in 2025 by circa £0.6m compared to 2024.

 

Outlook

The Group will continue to focus on delivering further operational efficiencies and reducing costs, while also reducing net debt and leverage. Whilst 2024 did not meet the full expectations of the Board, our US business delivered good growth during the year. The Group has made a solid start to 2025 and is confident of its ability to continue to reduce debt and increase margins and Underlying EBITDA.

 

Richard Peck, Chief Executive Officer commented:

"Whilst total revenue and Underlying EBITDA for the Group in 2024 was behind our original expectations, revenue growth was achieved in the second half of the year. I am also pleased that the Group increased its gross profit margin for the full year. During the period, we continued to focus on our operational efficiencies and, despite the inflationary pressures experienced in 2024, our operational costs have remained flat. The Group has also reduced net debt while investing in significant additional manufacturing capacity which is now operational, following the successful completion of construction in Vietnam.

 

"2025 has started well and our key objectives for the year are to raise the Group's revenue and increase our Underlying EBITDA margins across the Group while continuing to reduce our net debt."

 

 

1. Constant exchange rates: figures at constant exchange rates have been calculated using the average exchange rates in effect for the corresponding period in the relevant comparative year.

2. Company compiled market expectation - Revenue c.£197m and Underlying EBITDA £17.4m to £17.9m.

 

For further information please contact:

Inspecs Group plc

Richard Peck (CEO)

Chris Kay (CFO)

 

via FTI Consulting

Tel: +44 (0) 20 3727 1000

Peel Hunt (Nominated Adviser and Broker)

George Sellar

Andrew Clark

 

 

Tel: +44 (0) 20 7418 8900

FTI Consulting (Financial PR)

Alex Beagley

Harriet Jackson

Amy Goldup

 

 

Tel: +44 (0) 20 3727 1000

About INSPECS Group plc

INSPECS is a leading provider of eyewear solutions to the global eyewear market. The Group produces a broad range of eyewear frames, low vision aids and lenses, covering optical, sunglasses and safety, which are either "Branded" (under licence or under the Group's own proprietary brands), or "OEM" (unbranded or private label on behalf of retail customers).

INSPECS is building a global eyewear business through its vertically integrated business model. Its continued growth is underpinned by six core pillars: increasing the penetration of its own-brand portfolio, increasing distribution, growing its travel retail markets, maximising group synergies, expanding its manufacturing capacity and scaling the research and development department as it develops new and innovative eyewear products. The Group has operations across the globe: with offices and subsidiaries in the UK, Germany, Portugal, Scandinavia, the US and China (including Hong Kong, Macau and Shenzhen), and manufacturing facilities in Vietnam, China, the UK and Italy.

INSPECS customers are global optical and non-optical retailers, global distributors and independent opticians. Its distribution network covers over 80 countries and reaches approximately 75,000 points of sale.

More information is available at: www.INSPECS.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKCBPCBKDODB
Date   Source Headline
7th Sep 20227:00 amRNSDirector/PDMR Share Dealing
30th Aug 20224:52 pmRNSHolding(s) in Company
23rd Aug 20225:02 pmRNSHolding(s) in Company
18th Aug 20227:00 amRNSInterim Results
11th Aug 20223:31 pmRNSResult of AGM
11th Jul 20221:19 pmRNSDirector/PDMR Shareholding
4th Jul 20227:00 amRNSDirector/PDMR Shareholding
1st Jul 20222:26 pmRNSDirector/PDMR Dealing
29th Jun 202212:37 pmRNSDirector/PDMR Shareholding
29th Jun 20227:00 amRNSFinal Results
24th Jun 20227:00 amRNSNotice of Final Results
7th Jun 20224:38 pmRNSHolding(s) in Company
31st May 202211:14 amRNSHolding(s) in Company
17th May 20225:41 pmRNSChange to Publication Date of Results
27th Apr 20227:00 amRNSQ1 Trading Update and Notice of Results
31st Mar 20224:17 pmRNSDirector/PDMR Share Dealing
18th Mar 202210:09 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector/PDMR Share Dealing
1st Feb 20227:00 amRNSFull Year Trading Update
24th Jan 20227:00 amRNSHolding(s) in Company
11th Jan 20227:00 amRNSHolding(s) in Company
6th Jan 20227:00 amRNSAllotment of shares
24th Dec 20218:14 amRNSDirector/PDMR Share Dealing
23rd Dec 20217:00 amRNSAcquisition of Ego Eyewear
8th Dec 20217:00 amRNSAcquisition of BoDe
28th Oct 20217:00 amRNSQ3 Trading Update
20th Oct 20215:13 pmRNSHolding(s) in Company
8th Sep 20217:00 amRNSInterim Results
13th Aug 20217:00 amRNSNotice of Results
19th Jul 202111:42 amRNSResult of AGM
25th Jun 20217:00 amRNSAnnual Report and Notice of Annual General Meeting
21st Jun 20217:00 amRNSDirector/PDMR Dealing
18th Jun 20217:00 amRNSFinal Results
29th Apr 20217:00 amRNSQ1 Trading Update & Notice of Results
26th Feb 20217:00 amRNSDirector/PDMR LTIP Awards
8th Feb 20215:57 pmRNSHolding(s) in Company
29th Jan 20217:00 amRNSFull Year Trading Update
13th Jan 20218:25 amRNSHolding(s) in Company
23rd Dec 20204:21 pmRNSDirector/PDMR LTIP Awards
11th Dec 20201:05 pmRNSHolding(s) in Company
11th Dec 202012:00 pmRNSHolding(s) in Company
11th Dec 202011:58 amRNSDirector/PDMR Share Dealings
10th Dec 20203:11 pmRNSEschenbach Acquisition satisfaction of condition
7th Dec 20201:01 pmRNSResult of General Meeting
20th Nov 20207:00 amRNSPublication of Circular and Notice of GM
19th Nov 20202:05 pmRNSResult of Placing and Total Voting Rights
19th Nov 20207:00 amRNSProposed Placing
19th Nov 20207:00 amRNSProposed Acquisition of Eschenbach Holding GmbH
14th Oct 20201:53 pmRNSHolding(s) in Company
7th Oct 202012:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.